Vertex Q4 Earnings On Deck: Will This Biotech Heavyweight Keep Its Edge?

Zinger Key Points

Vertex reports Q4 earnings Monday, with Wall Street expecting $4.03 EPS and $2.78 billion revenue.
Strong technicals support VRTX stock, but selling pressure and pipeline execution remain key risks for 2025.
Brand New Membership Level: Benzinga Trade Alerts

Vertex Pharmaceuticals Inc VRTX is set to report fourth quarter earnings after the market closes Monday. Biotech investors are bracing for impact.

Chart created using Benzinga Pro

The stock has climbed 15.66% year-to-date, recovering from last year's volatility. With selling pressure creeping in, the question is whether this rally has legs, or if it’s time for a reset.

Wall Street's Expectations: Solid Numbers Or A Reality Check?

Wall Street expects Vertex to post EPS of $4.03 on revenue of $2.78 billion, per Benzinga Pro data.

But beyond the numbers, the real focus is on the company's upcoming drug launches and how they could fuel future growth.

Pipeline Watch: Can Alyftrek And Suzetrigine Deliver?

JPMorgan analyst Jessica Fye sees 2025 as a make-or-break year for Vertex.

The company is rolling out Alyftrek, its latest cystic fibrosis (CF) treatment and preparing for a potential suzetrigine launch in acute pain. Investors will be watching management's commentary on these new products closely, especially after suzetrigine's mixed Phase II results in LSR (large sensory neuropathy).

Fye expects a solid launch for Alyftrek, modeling $376 million in 2025 revenue though but suzetrigine's adoption remains uncertain, with pricing a key factor.

VRTX Stock Technicals: Bullish, But With Risks

Technicals are giving mixed signals. VRTX stock is trading at $469.32, above its eight-day, 20-day, 50-day and 200-day moving averages, flashing buy signals across the board.

The MACD (moving average convergence/divergence) indicator is bullish. RSI (relative strength index) at 62.06 suggests there’s still room to run.

But selling pressure is creeping in, hinting at potential turbulence ahead.

Can Vertex Stock Keep Its Momentum?

Vertex needs to deliver more than just a solid quarter though investors want confidence in its 2025 pipeline. Any slip-up in guidance could shake the stock's recent momentum. Stay tuned.

Read Next: